← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Evrys Bio, Llc
Doylestown, PA
$12,942,184
Total funding
7
Grants
Funding over time
peak $2M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,942,184 · 7
By mechanism
R44$11,392,186 · 3
R01$875,000 · 1
R43$674,998 · 3
Investigators at Evrys Bio, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS$1,000,000
R44 · FY2019 · AI
A single antiviral to treat multiple opportunistic infections$1,000,000
R44 · FY2021 · AI
A single antiviral to treat multiple opportunistic infections$1,000,000
R44 · FY2020 · AI
SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS$1,000,000
R44 · FY2018 · AI
A single antiviral to treat multiple opportunistic infections$999,998
R44 · FY2023 · AI
A single antiviral to treat multiple opportunistic infections$999,997
R44 · FY2019 · AI
A single antiviral to treat multiple opportunistic infections$983,882
R44 · FY2024 · AI
A single antiviral to treat multiple opportunistic infections$978,771
R44 · FY2025 · AI
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure$961,797
R44 · FY2025 · AI
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure$961,797
R44 · FY2024 · AI
A single antiviral to treat multiple opportunistic infections$901,086
R44 · FY2020 · AI
Mechanisms of Human Cytomegalovirus Latency$437,500
R01 · FY2015 · AI
Mechanisms of Human Cytomegalovirus Latency$437,500
R01 · FY2016 · AI
SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS$304,858
R44 · FY2016 · AI
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure$300,000
R44 · FY2021 · AI
Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz$225,000
R43 · FY2014 · AI
An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(PML)$224,999
R43 · FY2015 · AI
A Single Antiviral to Treat Multiple Opportunistic Infections$224,999
R43 · FY2014 · AI